Harmony Biosciences
HRMY
57 hedge funds and large institutions have $907M invested in Harmony Biosciences in 2021 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 22 increasing their positions, 15 reducing their positions, and 12 closing their positions.
47% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 15
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
0.86% less ownership
Funds ownership: 49.14% → 48.28% (-0.86%)
3% less funds holding
Funds holding: 59 → 57 (-2)
9% less capital invested
Capital invested by funds: $998M → $907M (-$90.6M)
17% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$22.5M |
| 2 |
ACM
Ashford Capital Management
Wilmington,
Delaware
|
+$13.1M |
| 3 |
BCM
Burrage Capital Management
Boston,
Massachusetts
|
+$5.26M |
| 4 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
+$3.95M |
| 5 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$3.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$23.7M |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$10M |
| 3 |
SPPAM
Summit Partners Public Asset Management
Boston,
Massachusetts
|
-$9.29M |
| 4 |
PA
Perceptive Advisors
New York
|
-$6.7M |
| 5 |
William Blair Investment Management
Chicago,
Illinois
|
-$5.57M |
HRMY Hedge Fund Activity: Q1 2021 in Review
57 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Harmony Biosciences (HRMY) for Q1 2021, worth a combined $907M — down 9.1% from $998M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of HRMY and 10 opened new positions — a net loss of 2 holders — while 15 trimmed existing stakes and 22 added.
The largest buyer was Vanguard Group, adding an estimated $22.5M. The largest seller was Fidelity Investments, cutting an estimated $23.7M.
- 57 institutional investors held Harmony Biosciences (HRMY) as of Q1 2021, down from 59 in Q4 2020.
- Funds reported $907M of Harmony Biosciences stock for Q1 2021, down 9.1% quarter-over-quarter.
- 10 funds opened new Harmony Biosciences positions in Q1 2021 and 12 closed out, a net change of -2 holders.
- The largest Harmony Biosciences buyer in Q1 2021 was Vanguard Group, an estimated $22.5M added.
- The largest Harmony Biosciences seller in Q1 2021 was Fidelity Investments, an estimated $23.7M sold.
Based on aggregated 13F filings for Q1 2021.